Advances in prostate cancer

Current Opinion in Oncology

Volumn 16, Issue 3, 2004, Pages 242-246

  Ryan, Charles J ^a   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiandrogen withdrawal; Antiandrogens; Chemoprevention; Chemotherapy; Corticosteroids; Hormonal therapy; Prostate cancer; Secondary hormonal therapy

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; CALCITRIOL; CLODRONIC ACID; DOCETAXEL; ESTRAMUSTINE; FINASTERIDE; KETOCONAZOLE; MITOXANTRONE; PAMIDRONIC ACID; PHOSPHONIC ACID DERIVATIVE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG MEGADOSE; DRUG POTENCY; GENE MUTATION; HIGH RISK PATIENT; HORMONE SENSITIVITY; HUMAN; INCIDENCE; NAUSEA; PELVIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SEROLOGY; SEXUAL DYSFUNCTION; STATISTICAL SIGNIFICANCE; THROMBOSIS; VOMITING;

HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 2142645863     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200405000-00009     Document Type: Review

References (23)

1. Punglia RS, D'Amico AV, Catalona WJ, et al.: Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003, 349:335-342. This paper suggests that lowering the threshold of a normal PSA to ≥2.5 ng/mL will double the detection rate of disease for men under 60.
2. Thompson I, Goodman PM, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-224. This paper showed a decreased incidence of prostate cancer in men treated with finasteride; however, a higher risk of high-grade tumors in the finasteride-treated patients tempers enthusiasm for this approach.
3. Madalinska JB, Easink-Bot ML, de Koning HJ, et al.: Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001, 19:1619-1628.
4. Penson DF, Feng Z, Kuniyuki A, et al.: General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol 2003, 21:1147-1154.
5. Segal RJ, Reid RD, Courneya KS, et al.: Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003, 21:1653-1659. This paper reports that weight training decreases fatigue and increases quality of life in men treated with androgen deprivation.
6. Kollermann J, Caprano J, Budde A, et al.: Follow-up of nondetectable prostate carcinoma (pTO) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy. Urology 2003, 62:476-480.
7. Bolla M, Gonzalez D, Warde P, et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 295-300.
8. Pilepich MV, Caplan R, Byhardt RW, et al.: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997, 15:1013-1021.
9. Roach M 3rd, DeSilvio M, Lawton C, et al.: Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003, 21:1904-1911. This paper establishes neoadjuvant androgen deprivation in conjunction with whole pelvis and prostate radiation as a standard of care for patients with high-risk localized disease.
10. Rini BWV, Bok R, Small EJ: Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 2003, 21:99-105.
11. Saad F, Gleason DM, Murray R, et al.: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
12. Dearnaley DP, Sydes MR, Mason MD, et al.: A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PRO5 Trial). J Natl Cancer Inst 2003, 95:1300-1311.
13. Edwards J, Krishna NS, Grigor KM, et al.: Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003, 89:552-556.
14. Hara T, Miyazaki J, Araki H, et al.: Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003, 63:149-153.
15. Taplin M, Rajeshkumar B, Halabi S, et al.: Androgen receptor mutations in androgen-independent prostate cancer: cancer and leukemia group B study 9663. J Clin Oncol 2003, 21:2673-2678.
16. Kassouf W, Tanguay S, Aprikian A: Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 2003, 169:1742-1744. This paper demonstrates that a previous antiandrogen withdrawal response increases the likelihood for a response to nilutamide.
17. Oh WK, Tully P, Kantoff PW, et al.: Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma. Cancer 2003, 97:2171-2179. This paper reports survey data indicating the widespread acceptance of chemotherapy in patients with HRPC.
18. Beer TM, Eilers KM, Garzotto M, et al.: Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003, 21:123-128.
19. Berry W, Dakhil S, Modiano M, et al.: Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002, 168:2439-2443.
20. Small EJ, Meyer M, Marshall ME, et al.: Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000, 18:1440-1450.
21. Tannock IF, Osoba D, Stockler MR, et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756-1764.
22. Small E, Smith MR, Seaman JJ, et al.: Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003, 21:4277-4284.
23. Ernst DS, Tannock IF, Winquist EW, et al.: Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003, 21:3335-3342.